Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with <scp>mTOR</scp> inhibitor (Vistusertib) in endometrial cancer: translational study from the <scp>VICTORIA</scp> trial in collaboration with the <scp>GINECO</scp> group-Reference-Cited by-同舟云学术

Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group

Published:2022-12-07 Issue:1 Volume:17 Page:27-36
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Mourksi Nour‐El‐Houda¹²³^ORCID,Dalban Cécile⁴,Colombe‐Vermorel Amélie⁵,Odeyer Laetitia⁵,Simioni Valentin¹²³,Frenel Jean‐Sébastien⁶,Fabbro Michel⁷,Bazan Fernando⁸,Abadie‐Lacourtoisie Sophie⁹,Coquan Elodie¹⁰,Martinez Séverine¹¹,Garin Gwenaelle⁴,Tabone‐Eglinger Séverine¹¹,Treilleux Isabelle⁵,Chabaud Sylvie⁴,Pérol David⁴,Ray‐Coquard Isabelle¹²,Heudel Pierre‐Etienne¹²,Diaz Jean‐Jacques¹²³,Marcel Virginie¹²³^ORCID

Affiliation:

1. Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon 1, Centre Léon Bérard Université de Lyon Lyon France

2. Institut Convergence PLAsCAN Lyon France

3. DevWeCan Labex Laboratory Lyon France

4. Clinical Research Department Centre Léon Bérard Lyon France

5. Biopathology Department Centre Léon Bérard, GINECO Lyon France

6. Medical Oncology Department, Institut Cancérologie de l'Ouest, and GINEGEPS St Herblain France

7. Department of Surgical Oncology, Institut du Cancer de Montpellier University of Montpellier Montpellier France

8. Department of Medical Oncology University Hospital of Besançon Besançon France

9. Institut de Cancérologie de l'Ouest Angers France

10. Department of Clinical Research, Department of Medical Oncology Comprehensive Cancer Centre François Baclesse Caen France

11. Biological Resource Center, Centre Léon Bérard Lyon France

12. Medical Oncology Department Centre Léon Bérard and University Claude Bernard Lyon 1, GINECO Lyon France

Funder

Institut National Du Cancer

Ligue Contre le Cancer

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13340

Reference28 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Endometrial cancer

3. Endometrial Cancer

4. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

5. Targeting mTOR for cancer therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling;Cellular & Molecular Biology Letters;2024-05-02